Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy

[1]  D. Coso,et al.  Entecavir as a first‐line treatment for HBV reactivation following polychemotherapy for lymphoma , 2008, British journal of haematology.

[2]  J. Hoofnagle,et al.  Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy , 2008, Annals of Internal Medicine.

[3]  C. Hsiung,et al.  A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial , 2008, Hepatology.

[4]  Wen-Qi Jiang,et al.  Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma , 2006, Cancer.

[5]  A. Cross,et al.  A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.

[6]  Ching-Lung Lai,et al.  Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.

[7]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  W. Yeo,et al.  Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients , 2004, Breast Cancer Research and Treatment.

[9]  P. Angus,et al.  Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine , 2004, Antimicrobial Agents and Chemotherapy.

[10]  B. McMahon,et al.  Chronic hepatitis B: Update of recommendations , 2004, Hepatology.

[11]  R. Perrillo.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. , 2001, Gastroenterology.

[12]  J. Villeneuve,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2000, Hepatology.

[13]  E. Jury.  EASL International Consensus Conference on Hepatitis C , 1999, Journal of hepatology.

[14]  G. Lau,et al.  Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  N. Leung,et al.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. , 1998, The New England journal of medicine.

[16]  R. Colonno,et al.  Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus , 1997, Antimicrobial agents and chemotherapy.

[17]  E. Elias,et al.  Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine , 1996, Hepatology.

[18]  A. Zuckerman,et al.  FULMINANT HEPATIC FAILURE IN LEUKAEMIA AND CHORIOCARCINOMA RELATED TO WITHDRAWAL OF CYTOTOXIC DRUG THERAPY , 1975, The Lancet.

[19]  J. Wands,et al.  Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. , 1975, Gastroenterology.

[20]  A. Skulberg,et al.  Letter: Occupational hazard of halothane. , 1974, Lancet.